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Abstract
Background: Cancer risk and Lhermitte-Duclos disease (LDD) risk estimates for Cowden syndrome (CS) are broad and 
based on a small number of patients. Risk estimates are vital to the development of diagnostic criteria, genetic 
counseling, and cancer surveillance. To further elaborate and estimate the risks associated with CS, a large cohort of 
patients was evaluated.
Methods: CS patients were identified from the medical literature and the Mayo Clinic's records. All patients met 
accepted diagnostic criteria for CS.
Results: A total of 211 CS patients (age 44 ± 16 years, 64% female, 46% PTEN mutation) were included (published 
literature 90% and Mayo Clinic series 10%). The cumulative lifetime (age 70 years) risks were 89% for any cancer 
diagnosis (95% confidence interval (CI) = 80%,95%), breast cancer [female] 81% (CI = 66%,90%), LDD 32% (CI = 
19%,49%), thyroid cancer 21% (CI = 14%,29%), endometrial cancer 19% (CI = 10%,32%), and renal cancer 15% (CI = 
6%,32%). A previously unreported increased lifetime risk for colorectal cancer was identified (16%, CI = 8%,24%). Male 
CS patients had fewer cancers diagnosed than female patients and often had cancers not classically associated with CS. 
Seven percent of breast and thyroid cancers occurred in patients who were younger than the recommended age to 
commence radiographic cancer screening. There was a trend for patients with a family history of CS and PTEN 
mutations to have a lower cancer risk than those without.
Conclusions: This study confirms CS patients are at increased risk for cancer and quantitative data is provided to guide 
clinical care. Based on a different tumor spectrum, separate male and female clinical CS diagnostic criteria may be 
indicated.
Background
Cowden syndrome (CS) is an autosomal dominant disor-
der characterized by benign hamartomas and an
increased risk of breast, thyroid, and other cancers (Table
1) [1]. CS is one of several syndromes associated with ger-
mline mutations in the PTEN gene, including Bannayan-
Riley-Ruvalcaba syndrome, Proteus or Proteus-like syn-
drome, adult Lhermitte-Duclos disease (LDD), and
autism-like disorders associated with macrocephaly [2-5].
Previously reported CS associated cancer risk profiles
have varied and are usually illustrated with wide varia-
tions. The commonly quoted risks are 25-50% for breast
cancer, 5-10% for endometrial cancer, and 3-10% for thy-
roid cancer [6]. These estimates are based on a collection
of case series, each often comprising a small number of
patients. In addition to cancer, CS patients are at risk for
LDD. LDD is the eponym for a dysplastic cerebellar gan-
gliocytoma, which is pathognomonic for CS. The inci-
dence of LDD in CS is unclear. LDD is usually considered
to be a hamartoma and not a cancer, but may still have
serious consequences and therefore was included in this
study.
As there is a limited evidence base for CS cancer and
LDD risks, counseling patients regarding their risks and
appropriate surveillance is challenging. This study aims
to clarify these issues by reporting cumulative cancer and
LDD diagnoses in a large group of CS patients.
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Methods
The patient cohort was derived from both the published
medical literature and the records of the Mayo Clinic
(Rochester, Minnesota). The Mayo Clinic Institutional
Review Board (IRB) approved this study. Patients from
the medical literature were identified by searching http://
www.pubmed.com using the terms "Cowden's syndrome"
and "Cowden syndrome." Further reports were identified
by reviewing the references listed in the initial publica-
tions retrieved. Mayo Clinic CS patients were identified
through a search of medical records from January 1, 1996
to June 30, 2008 for any patients with the keyword
"Cowden" in their records.
Inclusion criteria required all patients to meet accepted
diagnostic criteria for CS (Table 1). Patient data was
entered into the study database by one author. The data-
base was audited for accuracy by the other authors by
reviewing the source information (literature or medical
record) for each patient. Importantly, all cases were
reviewed to determine if they had been published more
than once (duplicate publication). Where the same
patient had been published more than once, only the
most recent report was included. In some medical litera-
ture cases, the age of cancer diagnosis was unclear (for
example, "patient had thyroid cancer in their 20 s"). In
these cases, the authors made a best estimate. Statistical
analysis was performed with JMP 8.0 (SAS Institute,
Cary, North Carolina).
Results
A total of 211 patients were included in the final version
of the study database, 90% from the literature (n = 190)
and 10% from the Mayo Clinic (n = 21). Cumulative life-
time (age 70 years) risk estimates were made with 210
patients; one literature patient had to be excluded as age
data was not available. The literature patients were iden-
tified from review of 99 publications. Thirty one addi-
tional publications were identified in the literature search
for review but were unavailable from the Mayo Medical
Library or via inter-library loan. To date, information per-
taining to individuals from the Mayo Clinic series had not
been published. Patient demographics revealed that the
majority were female (64%, n = 136) with a mean age at
most recent follow up of 44 ± 16 years.
Most patients had been diagnosed with cancer or LDD
(62%, n = 130), and a quarter (24%, n = 50) had been diag-
nosed with either two cancers or a cancer with a LDD
diagnosis. Clinical arrays were made to show the cancer
and LDD diagnoses in the study patients (Figure 1 -
females; Figure 2 - males). The cumulative lifetime can-
cer risks are highlighted in Table 2 and Figure 3. The most
commonly reported cancer was breast cancer in females
(Figure 4). Of female CS patients diagnosed with breast
cancer, 34% had bilateral disease (n = 21). In the 15 cases
of bilateral breast cancer where there was adequate data
to determine metachronous or synchronous status, 8
were synchronous and 7 were metachronous. Several rare
cancers were reported in one or only a few CS patients
including testicular germ cell tumor and trichilemmomal
carcinoma [7,8].
The cumulative CS cancer risks (but not overall cancer
risks) found in this study were higher than the ranges
reported in the literature (Table 3). The Mayo Clinic and
medical literature cases had a similar total percentage of
cancer/LDD cases (62% and 61%, respectively). The most
striking difference between the Mayo Clinic and litera-
ture cases was the diagnosis of LDD. LDD was not
Table 1: Diagnostic criteria for Cowden syndrome in individuals without a family history
Pathognomonic criteria Lhermitte-Duclos disease (dysplastic cerebellar gangliocytoma) Mucocutaneous features: Six or more facial 
papules, ≥3 must be trichilemmomas, or Cutaneous facial papules and oral mucosal papillomatosis, or Oral 
mucosal papillomatosis and acral keratoses, or Six or more palmo-plantar keratoses
Major criteria Breast cancer
Thyroid cancer (especially follicular)
Endometrial cancer
Macrocephaly (≥ 97% percentile)
Minor criteria Other structural thyroid lesions (for example, multinodular goiter)
Mental retardation (IQ ≤ 75)
Gastrointestinal hamartomas
Fibrocystic breast disease
Lipomas
Fibromas
Genitourinary tumors (examples include, uterine fibroids and renal cell carcinoma)
Genitourinary structural malformations
Diagnostic criteria for Cowden syndrome is met in individuals without a family history if there are any of the following: 1) Adult Lhermitte-
Duclos disease or the required mucocutaneous features; 2) Two major criteria 3) One major and three minor criteria; 4) Four minor criteria. 
Adapted from Eng [15]. See Eng for complete criteria.Riegert-Johnson et al. Hereditary Cancer in Clinical Practice 2010, 8:6
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observed in any Mayo Clinic CS cases, while it was diag-
nosed in 15% of the literature cases.
Less than half of male CS patients had a cancer or LDD
diagnosis compared to the majority of females with CS
(males 45% vs. females 70%). Many males with a cancer
diagnosis did not have cancers usually associated with CS
(i.e. LDD, breast, thyroid, and renal cancer) (Figure 2).
These cancers included three cases of lung adenocarci-
noma and solitary cases of carcinoid, testicular semi-
noma, testicular cancer, trichilemmomal carcinoma,
prostate adenocarcinoma, hepatocellular carcinoma,
melanoma, transitional cell carcinoma of the bladder,
anal squamous cell cancer.
The screening commencement age to encompass 100%
of cases varied between cancer types (Table 4). The larg-
est difference was between LDD and colorectal cancer; to
capture 100% cases of LDD, screening would need to
begin at age 9, while the detection of 100% of colorectal
cancers would require screening beginning at age 43. The
number of additional years of screening needed to
improve from 95 to 100% case capture was 3-7 years
except for endometrial cancer where 10 years would be
needed.
A family history or a possible family history of CS was
noted in 53% (n = 111). A PTEN mutation was identified
in 46% of patients overall and in 92% of those that had
PTEN  testing (97 of 105 were mutation positive). The
spectrum of PTEN  mutations reported was nonsense
(41%, n = 40), missense (14%, n = 14), splice site and other
(12%, n = 12), and mutation found but type not noted
(32%, n = 31). In patients who had PTEN testing, one of
four patients without an identifiable mutation had breast
cancer compared to 24 of 64 with an identifiable muta-
tion being diagnosed with breast cancer (25% vs. 38%, p =
0.5 Fisher's exact test).
There was no obvious association of the diagnosis of
one cancer with the diagnosis of another cancer (as an
example, patients who were diagnosed with breast cancer
were no more likely to be diagnosed with thyroid cancer
than patients who did not have breast cancer) (Figures 1
and 2). Family history of CS or a reported PTEN mutation
w e r e  l e s s  l i k e l y  t o  oc cu r  i n  t h e  ca n c e r  gr o u p ,  b u t  t h is
trend was not statistically significant (family history odds
ratio (OR) 0.6 95% confidence interval (CI) = 0.4, 1.1;
PTEN mutation OR 0.7, 95% CI = 0.4, 1.1).
Discussion
W e report that cumulative lifetime CS cancer risks are
higher than those previously published. Previously
reported risks were overall estimates from small groups
of patients. The large cohort of patients studied in this
report made it possible to determine cumulative risks
with adjustment for the number of patients at risk at a
particular age (Kaplan-Meier estimation). The presented
findings highlight the importance of determining cumu-
lative lifetime risks in hereditary cancer syndromes.
Figure 1 A clinical array of the cancer and Lhermitte-Duclos disease (LDD) diagnoses in the 136 female Cowden syndrome patients includ-
ed in the study. Each column of rectangles represents an individual patient. A diagnosis is indicated by a shaded box containing a "1". Rows represent 
cancer or LDD diagnosis: BCA (pink) - breast cancer (n = 61 cases); BBC (magenta) - bilateral breast cancer (n = 21 cases); LDD (teal) - Lhermitte-Duclos 
disease (n = 24 cases); TCA (yellow) - thyroid cancer (n = 23 cases); ECA (violet) - endometrial cancer (n = 12 cases); RCA (blue) - renal cancer (n = 5 
cases); SCA (green) - skin cancer (n = 8 cases); Oth (grey) - other cancers (n = 12 cases); CRC (brown) - colorectal cancer (n = 5 cases). Patients were 
sorted into groups and subgroups by cancer diagnosis (hierarchical sorting). This aids identification of the clustering of one cancer diagnosis with 
another. Patients were first sorted into those with and without breast cancer. Those with breast cancer were then sorted into those with and without 
bilateral breast cancer. Each of the subgroups (breast cancer, bilateral breast cancer, and no breast cancer) were then sorted into those with and with-
out LDD and then into those with and without thyroid cancer. Figure formatting taken from Faghri and others [14].Riegert-Johnson et al. Hereditary Cancer in Clinical Practice 2010, 8:6
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Ascertainment and publication biases both may have
artificially elevated the risks reported here. Evidence of
publication bias includes that the proportion of patients
with LDD was much higher in the medical literature than
the unpublished Mayo Clinic series. As cases of LDD are
rare, they are more likely to be published as case reports.
Ascertainment and publication bias can be corrected for
by excluding probands from the analysis. This approach
would have left only 23 patients; a number too small for
meaningful analysis.
The National Cancer Comprehensive Network
(NCCN) issues the most widely used cancer surveillance
Figure 2 A clinical array of the cancer and Lhermitte-Duclos disease (LDD) diagnoses in the 75 male Cowden syndrome patients included 
in the study. See the caption of Figure 1 for an explanation of figure color coding and formatting. The diagnoses were LDD n = 11 cases, thyroid 
cancer n = 5 cases, other cancers n = 12 cases, skin cancer n = 5 cases, colorectal cancer n = 5 cases, renal cancer n = 3 cases, and breast cancer n = 
2 cases. Patients were sorted into groups and subgroups by cancer diagnosis (hierarchical sorting). Patients were first sorted into those with and with-
out LDD. Then those with LDD were sorted into those with and without thyroid cancer. Next the subgroups were sorted into those with and without 
other cancers, followed by those with and without skin cancer.
Figure 3 Cumulative risk of any cancer diagnosis in female (red) 
and male (blue) patients with Cowden syndrome from birth to 
age 70 (Kaplan-Meier).
Figure 4 Cumulative risk of breast cancer diagnosis in female pa-
tients with Cowden syndrome (CS) from birth to age 70 (Kaplan-
Meier). Sixty-one of 136 female CS patients and 2 of 75 male CS pa-
tients were diagnosed with breast cancer.Riegert-Johnson et al. Hereditary Cancer in Clinical Practice 2010, 8:6
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guidelines for CS (Table 5) [9]. The findings of this study
confirm the current NCCN guidelines as the initial start-
ing point for prescribing an individual CS cancer surveil-
lance program. The age at which to begin cancer
s c r e e n i n g  i s  a  k e y  q u e s t i o n  i n  h e r e d i t a r y  c a n c e r  s y n -
drome surveillance (the interval for testing is assumed to
be one year and the test is usually an imaging modality or
an endoscopy). In the authors' collective experience,
patients and care providers initially request screening
beginning at the age of the youngest reported case of can-
cer. The NCCN recommends mammography and breast
magnetic resonance imaging (MRI) to commence at 30 -
35 years for most CS patients (those without a family his-
tory of breast cancer). For thyroid cancer surveillance,
NCCN recommends an initial thyroid ultrasound at age
18 years. Seven percent of CS breast and thyroid cancers
occurred prior to the recommended onset of radio-
graphic screening by NCCN. In order to capture 100% of
reported breast and thyroid cancer cases with imaging,
breast screening would need to commence at age 21 (9
years younger than recommend by NCCN) and thyroid
screening at age 10 (8 years younger than recommended
by NCCN). Lowering the recommended age of screening
to encompass all reported cases, results in screening a
group with only a small chance of being diagnosed with
cancer. The authors often utilize data from studies such
as this one to illustrate this concept for patients. For
example, if an annual breast MRI was performed on this
study's female cohort from ages 21 (the age of the young-
est reported case) to 30 (the recommended NCCN start
age), approximately 800 breast MRIs would be performed
in a cohort with only four breast cancer diagnoses (0.5%).
Also, about 80 of the 800 breast MRIs (10%) would
require a recall of the patient for further testing possibly
including breast biopsy [10].
CS patients often have colorectal polyps, and it has
been unclear if these polyps place such patients at
increased risk for colorectal cancer (CRC) [6,11]. Current
recommendations are that CS patients should have aver-
age risk CRC screening with colonoscopy beginning at 50
years of age [9,12]. The elevated CRC risk identified here
would support earlier and more intense screening. The
authors recommend colonoscopy beginning at age 45 and
every 5 years thereafter.
Table 2: Cumulative cancer risk by age and site in 210 patients with Cowden syndrome (95% confidence intervals)
Site 20 yrs 30 yrs 40 yrs 50 yrs 60 yrs 70 yrs
All cancers 9% (6-13) 18% (13-24) 35% (29-43) 63% (46-70) 78% (70-85) 89% (80-95)
Breast [female] 0 4% (2-10) 19% (12-27) 53% (42-63) 73% (61-83) 81% (66-90)
Lhermitte-Duclos 4% (2-8) 10% (6-15) 13% (9-19) 21% (15-28) 21% (15-28) 32% (19-49)
Thyroid 4% (0-5) 5% (10-29) 9% (6-15) 17% (12-25) 21% (14-29) 21% (14-29)
Endometrium 1% (0-5) 1% (0-5) 1% (0-5) 9% (5-19) 19% (10-32) 19% (10-32)
Colon and rectum 0 0 0 3% (1-10) 13% (7-25) 16% (8-24)
Kidney 0 1% (0-4) 1% (0-4) 3% (1-8) 7% (3-16) 15% (6-32)
Risks were estimated using Kaplan-Meier estimation. Table format from Hearle and others [16].
Table 3: Cowden syndrome and general population cancer risks
Site Literature† This study: Overall This study: 
Cumulative* (95% CI)
General population lifetime risk‡
Breast [female] 25-50% 45% 81% (66-90) 14%
Lhermitte-Duclos Not reported 15% 32% (19-49) Very rare
Thyroid 3-10% 12% 21% (14-29) 1%
Endometrium 5-10% 9% 19% (10-32) 3%
Colon and rectum Not reported 5% 16% (8-24) 6%
Kidney Not reported 4% 19% (10-32) 1%
* Cumulative lifetime (age 70) risks (95% confidence intervals). † From Pilarski [6]. ‡ General population lifetime cancer risks, except for LDD, 
are from the National Cancer Institute's Surveillance Epidemiology and End Result (SEER) database (http://seer.cancer.gov/csr/1975_2004/
results_merged/topic_lifetime_risk.pdf, accessed August 25th, 2009). The risks cited include both invasive cancer and in-situ disease.Riegert-Johnson et al. Hereditary Cancer in Clinical Practice 2010, 8:6
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This study did not identify any risk factors for cancer in
CS patients. This is consistent with the findings from
most other hereditary cancer syndromes. The patients
who had a family history consistent with CS had a trend
for lower cancer risk than those without a family history.
The most likely reason for this is, ascertainment bias;
patients with a family history were more likely to be iden-
tified by non-malignant CS signs such as skin findings
rather than cancer. There was also a trend for lower can-
cer risk in those with a PTEN mutation. This is possibly
the result of individuals suspected to have CS but who do
not have a cancer diagnosis having PTEN testing to con-
firm the diagnosis.
An association between an identified PTEN mutation
and breast cancer diagnosis in CS has been reported [13].
Our study does not support this association. The utility of
a  d e t a i l e d  g e n o t y p e / p h e n o t y p e  a n a l y s i s  o f  t h i s  s t u d y ' s
database is limited and was not performed for several
reasons. These include that only half of patients had
PTEN  testing and of those with a mutation identified
most had a nonsense mutation limiting the diversity of
mutation types.
Cancer and LDD are critical components to recogniz-
ing and diagnosing CS and the current CS diagnostic cri-
teria includes LDD, breast, thyroid, renal and
endometrial cancers. Most males did not have cancer and
many that did had cancers that are not usually associated
with CS. Developers of the clinical criteria for CS diagno-
sis should consider separate criteria for male and female
patients with the male criteria having a decreased empha-
sis on cancer diagnosis and inclusion of cancers not usu-
ally associated with CS. Regardless of the diagnostic
criteria used, clinicians should maintain a high degree of
suspicion for the often subtle signs of CS.
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Table 4: Ages to initiate screening to capture 95 and 100% of reported cancer cases by site
Site 95% of cases (yrs) 100% of cases (yrs)
Breast [female] 28 21
Lhermitte-Duclos disease 14 9
Thyroid 17 10
Endometrium 32 22
Colon and rectum 46 43
Kidney 33 28
The age that encompasses 100% of cancer cases for a particular site is also the age of the youngest reported case for that site.
Table 5: Cancer surveillance guidelines for Cowden syndrome
General Physical examination beginning at age 18 or 5 years before the diagnosis of breast or thyroid cancer in the family.
Thyroid Baseline ultrasound thyroid examination at age 18 and consider yearly thereafter.
Skin Annual dermatologic exam.
Colon None.
Breast [female] For those without a family history of breast cancer, self breast examination and clinical breast examination are 
recommended to commence at ages 18 and 25, respectively. Also, mammography and breast magnetic 
resonance imaging are recommended to begin at ages 30 to 35. Consider prophylactic mastectomy.
Endometrial [female] Educate on symptoms and consider enrollment in a clinical trial.
Adapted from the National Comprehensive Cancer Network (NCCN) guidelines for Cowden syndrome [9]. In addition to the NCCN 
recommendations, the authors recommend colon and rectum cancer screening with colonoscopy to begin at age 45 and every 5 years 
thereafter.Riegert-Johnson et al. Hereditary Cancer in Clinical Practice 2010, 8:6
http://www.hccpjournal.com/content/8/1/6
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